EP1168919A4 - Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion - Google Patents
Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletionInfo
- Publication number
- EP1168919A4 EP1168919A4 EP00919668A EP00919668A EP1168919A4 EP 1168919 A4 EP1168919 A4 EP 1168919A4 EP 00919668 A EP00919668 A EP 00919668A EP 00919668 A EP00919668 A EP 00919668A EP 1168919 A4 EP1168919 A4 EP 1168919A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bronchoconstriction
- ies
- allergy
- kit
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12795899P | 1999-04-06 | 1999-04-06 | |
US127958P | 1999-04-06 | ||
PCT/US2000/008020 WO2000062736A2 (en) | 1999-04-06 | 2000-03-24 | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1168919A2 EP1168919A2 (en) | 2002-01-09 |
EP1168919A4 true EP1168919A4 (en) | 2002-03-06 |
Family
ID=22432865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00919668A Ceased EP1168919A4 (en) | 1999-04-06 | 2000-03-24 | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1168919A4 (en) |
JP (1) | JP2003515525A (en) |
CN (1) | CN1330513A (en) |
AU (1) | AU4031700A (en) |
BR (1) | BR0006019A (en) |
CA (1) | CA2330022A1 (en) |
HK (1) | HK1042017A1 (en) |
IL (1) | IL140054A0 (en) |
WO (1) | WO2000062736A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737040B1 (en) | 1998-08-04 | 2004-05-18 | Diadexus, Inc. | Method and antibody for imaging breast cancer |
US6730477B1 (en) | 1998-08-04 | 2004-05-04 | Diadexus, Inc. | Method of diagnosing, monitoring and staging breast cancer |
AU3766900A (en) * | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | 47 human secreted proteins |
DE10049549A1 (en) | 2000-10-06 | 2002-05-02 | Markus Hecker | Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
EP1406667B1 (en) | 2001-07-06 | 2008-02-20 | Topigen Pharmaceuticals Inc. | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
WO2004086052A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b) |
US7671182B2 (en) * | 2003-03-31 | 2010-03-02 | Council Of Scientific & Industrial Research | Gene variants of signal transducer and activator of transcription-6 (STAT 6) variants and process of detection the same |
EA029094B9 (en) * | 2003-12-03 | 2018-04-30 | Коуда Терапьютикс, Инк. | Antisense compounds targeted to connexins and methods of use thereof |
WO2006010492A1 (en) * | 2004-07-28 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with tryptase 1 (tps1) |
US8673268B2 (en) | 2004-10-15 | 2014-03-18 | Galapagos N.V. | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
DK1809302T3 (en) * | 2004-10-20 | 2012-11-26 | Antisense Therapeutics Ltd | Antisense modulation of integrin alpha-4 expression |
EP1812075B1 (en) | 2004-10-29 | 2013-12-11 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
JP2008520684A (en) | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Fully human monoclonal antibody against IL-13 |
US8592384B2 (en) | 2005-04-04 | 2013-11-26 | The Board Of Regents Of The University Of Texas System | Micro-RNA's that regulate muscle cells |
WO2008021237A1 (en) * | 2006-08-10 | 2008-02-21 | Arubor Corporation | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
US8426581B2 (en) * | 2009-03-27 | 2013-04-23 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the FCεR1α gene |
US10208346B2 (en) * | 2013-04-19 | 2019-02-19 | Epiontis Gmbh | Method for identifying the quantitative cellular composition in a biological sample |
AU2019347849A1 (en) * | 2018-09-26 | 2021-05-20 | AUM LifeTech, Inc. | 2'FANA modified Foxp3 antisense oligonucleotides and methods of use thereof |
CN109260217A (en) * | 2018-09-30 | 2019-01-25 | 深圳松乐生物科技有限公司 | 3`- deoxyinosine nucleosides is in preparation for the application in a variety of disease drugs, food or health care product |
CN114591963B (en) * | 2022-05-10 | 2022-07-19 | 上海优替济生生物医药有限公司 | sgRNA and method for constructing GM-CSF (-) cell by using same |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010820A1 (en) * | 1991-11-26 | 1993-06-10 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
WO1993012756A2 (en) * | 1991-12-17 | 1993-07-08 | The Regents Of The University Of California | Transfection of lung via aerosolized transgene delivery |
WO1994002605A1 (en) * | 1992-07-22 | 1994-02-03 | Duke University | Dna encoding the human a1 adenosine receptor |
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
WO1996040266A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for asthma |
WO1998011211A2 (en) * | 1996-09-10 | 1998-03-19 | Hybridon, Inc. | METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES |
WO1998023294A1 (en) * | 1996-11-26 | 1998-06-04 | East Carolina University | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation |
WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
WO2000009525A2 (en) * | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
CZ154898A3 (en) * | 1995-11-21 | 1998-09-16 | Icn Pharmaceuticals, Inc. | Oligonucleotides for inhibiting growth of tumors mediated by il-8 and il-8 receptor |
PT1009413E (en) * | 1997-09-05 | 2007-05-31 | Univ California | Use of immunostimulatory oligonucleotides for preventing or treating asthma |
-
2000
- 2000-03-24 JP JP2000611873A patent/JP2003515525A/en not_active Withdrawn
- 2000-03-24 WO PCT/US2000/008020 patent/WO2000062736A2/en not_active Application Discontinuation
- 2000-03-24 BR BR0006019-4A patent/BR0006019A/en not_active IP Right Cessation
- 2000-03-24 CN CN00801046A patent/CN1330513A/en active Pending
- 2000-03-24 CA CA002330022A patent/CA2330022A1/en not_active Abandoned
- 2000-03-24 IL IL14005400A patent/IL140054A0/en unknown
- 2000-03-24 AU AU40317/00A patent/AU4031700A/en not_active Abandoned
- 2000-03-24 EP EP00919668A patent/EP1168919A4/en not_active Ceased
-
2002
- 2002-04-08 HK HK02102615.9A patent/HK1042017A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010820A1 (en) * | 1991-11-26 | 1993-06-10 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
WO1993012756A2 (en) * | 1991-12-17 | 1993-07-08 | The Regents Of The University Of California | Transfection of lung via aerosolized transgene delivery |
WO1994002605A1 (en) * | 1992-07-22 | 1994-02-03 | Duke University | Dna encoding the human a1 adenosine receptor |
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
WO1996040266A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for asthma |
WO1998011211A2 (en) * | 1996-09-10 | 1998-03-19 | Hybridon, Inc. | METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES |
WO1998023294A1 (en) * | 1996-11-26 | 1998-06-04 | East Carolina University | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation |
WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
WO2000009525A2 (en) * | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
Non-Patent Citations (5)
Title |
---|
LOAKES D ET AL: "5-NITROINDOLE AS AN UNIVERSAL BASE ANALOGUE", NUCLEIC ACIDS RESEARCH, vol. 22, no. 20, 1994, pages 4039 - 4043, XP000999195, ISSN: 0305-1048 * |
METZGER W JAMES ET AL: "Oligonucleotide therapy of allergic asthma.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 104, no. 2 PART 1, August 1999 (1999-08-01), pages 260 - 266, XP001024505, ISSN: 0091-6749 * |
NICHOLS R ET AL: "A UNIVERSAL NUCLEOSIDE FOR USE AT AMBIGOUS SITES IN DNA PRIMERS", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492 - 493, XP000560346, ISSN: 0028-0836 * |
OHTSUKA E ET AL: "AN ALTERNATIVE APPROACH TO DEOXYOLIGONUCLEOTIDES AS HYBRIDIZATION PROBES BY INSERTION OF DEOXYINOSINE AT AMBIGUOUS CODON POSITIONS", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605 - 2608, XP002031938 * |
RAHMAN M SAYEEDUR ET AL: "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenine in vivo and in vitro.", MUTATION RESEARCH, vol. 377, no. 2, 1997, pages 263 - 268, XP001024479, ISSN: 0027-5107 * |
Also Published As
Publication number | Publication date |
---|---|
IL140054A0 (en) | 2002-02-10 |
CA2330022A1 (en) | 2000-10-26 |
WO2000062736A3 (en) | 2001-10-11 |
CN1330513A (en) | 2002-01-09 |
BR0006019A (en) | 2001-03-13 |
AU4031700A (en) | 2000-11-02 |
EP1168919A2 (en) | 2002-01-09 |
WO2000062736A2 (en) | 2000-10-26 |
HK1042017A1 (en) | 2002-08-02 |
JP2003515525A (en) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL140054A0 (en) | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion | |
EP1222309A4 (en) | Human rnase h and oligonucleotide compositions thereof | |
EP1416961A4 (en) | Composition and method for the treatment of disease | |
PL342062A1 (en) | Method of treating sexual disorders among women | |
HK1103631A1 (en) | Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions | |
AU2002305236A8 (en) | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent | |
HK1062170A1 (en) | Process for the preparation of 1,3-substituted in denes and aryl-fused azapolycyclic compounds | |
EP1102786A4 (en) | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments | |
HK1041880A1 (en) | Compounds and methods for treatment of asthma, allergy and inflammatory disorders. | |
ZA200105293B (en) | Use of growth hormone secretagogues for treatment of physical performance decline. | |
AU9527001A (en) | Treatment of T cell disorders | |
EP1051169A4 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
AU6082101A (en) | Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate | |
EP1079764A4 (en) | The treatment of sexual dysfunction in certain patient groups | |
ZA200203435B (en) | Method and compositions for treating pulmonary diseases. | |
PL350902A1 (en) | Pyridothiene diazepins, method of obtaining them and pharmacological compositions containing them | |
AU2002348299A8 (en) | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions | |
ZA200105259B (en) | Use of growth hormone secretagogues for stimulating or increasing appetite. | |
AU2003258176A8 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
EP1261331A4 (en) | Method and compositions for treating fibrotic diseases | |
AU2001231987A1 (en) | Polyanionic polyglycosides in the treatment of autism | |
HUP0200466A3 (en) | Lipoglycan compositions and methods of treating parasitic infections | |
HUP0300043A3 (en) | Method and composition for the treatment of pain | |
AU2003258177A8 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001127 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020117 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 6/00 A |
|
17Q | First examination report despatched |
Effective date: 20020405 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20041017 |